Document is current
Any future updates will be listed below
-
Authors
Cheng, Wendy Y.
Fishman, Jesse
Yenikomshian, Mihran
Mahendran, Malena
Kunzweiler, Colin
Vu, Jensen Duy
Duh, Mei Sheng
-
Funding
Funding for this research was provided by:
Apellis Pharmaceuticals
- License Information
-
More Information
Article History
Received: 11 August 2023
Accepted: 30 October 2023
First Online: 24 November 2023
Declarations
:
: Mihran Yenikomshian, Malena Mahendran, and Mei Sheng Duh are employees of Analysis Group, Inc., which has received research funding from Apellis Pharmaceuticals, Inc. Jesse Fishman is an employee and owns stock/stock options of Apellis Pharmaceuticals, Inc. Wendy Y. Cheng, Colin Kunzweiler, and Jensen Duy Vu were employees of Analysis Group, Inc., at the time the study was conducted. Wendy Y. Cheng is currently an employee of Berkeley Research Group. Colin Kunzweiler is currently an employee and owns stock/stock options of Moderna Therapeutics, Inc. Jensen Duy Vu is currently an employee of Republic Note/VietChallenge.
: The authors thank the participants of the study. Analyses in the current study included only deidentified insurance claims data; thus, institutional review board approval, patient consent to participate in the study or for publication of study findings were not required. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments, and in compliance with the US patient confidentiality requirements of the Health Insurance Portability and Accountability Act.
